Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
High-dose IL-2 treatment for metastatic melanoma has been approved by the FDA in 1998.
Studies of GM-CSF plus IL-2 have not addressed the approved dose and schedule. This protocol
will study the combination of HD-IL2 and GM-CSF given the potential synergistic interactions
discussed above.